| Literature DB >> 24891323 |
Vincent H J van der Velden1, Patricia G Hoogeveen1, Dick de Ridder2, Magdalena Schindler-van der Struijk1, Menno C van Zelm1, Mathijs Sanders3, Dennis Karsch4, H Berna Beverloo5, King Lam6, Alberto Orfao7, Pieternella J Lugtenburg3, Sebastian Böttcher4, Jacques J M van Dongen1, Anton W Langerak1, Mies Kappers-Klunne3, Kirsten van Lom3.
Abstract
B-cell prolymphocytic leukemia (B-PLL) is a rare mature B-cell malignancy that may be hard to distinguish from mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). B-PLL cases with a t(11;14) were redefined as MCL in the World Health Organization 2008 classification. We evaluated 13 B-PLL patients [7 being t(11;14)-positive (B-PLL+) and 6 negative (B-PLL-)] and compared them with MCL and CLL patients. EuroFlow-based immunophenotyping showed significant overlap between B-PLL+ and B-PLL-, as well as between B-PLL and MCL, whereas CLL clustered separately. Immunogenotyping showed specific IGHV gene usage partly resembling MCL. Gene expression profiling showed no separation between B-PLL+ and B-PLL- but identified 3 subgroups. One B-PLL subgroup clustered close to CLL and another subgroup clustered with leukemic MCL; both were associated with prolonged survival. A third subgroup clustered close to nodal MCL and was associated with short survival. Gene expression profiles of both B-PLL+ and B-PLL- showed best resemblance with normal immunoglobulin M-only B-cells. Our data confirm that B-PLL+ is highly comparable to MCL, indicate that B-PLL- also may be considered as a specific subgroup of MCL, and suggest that B-PLL is part of a spectrum, ranging from CLL-like B-PLL, to leukemic MCL-like B-PLL, to nodal MCL-like B-PLL.Entities:
Mesh:
Year: 2014 PMID: 24891323 DOI: 10.1182/blood-2013-10-533869
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113